Here's some more background about the Resverlogix PAH program from a prior post, the March funding news release, some bromodomain/epigenetics PAH articles that rndtbl posted over on Investor Village, a link to the recent paper "Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension," and a link to the latest ClinicalTrials.gov listing.